Replimune Group, Inc.
NASDAQ:REPLBiotechnology
+$0.19 today
- Market cap
- $1.88B
- Beta
- 0.91
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.42
Volume 2.13M
Average 7.51M
REPL Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Operating Margin history
Percent of revenue · from the income statement
No Operating Margin data reported for this period type.
Operating Margin vs competitors
How REPL compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 42.3% | +95.9 pp | +514.7 pp | |
| LTM Aug 2026 | 41.3% | +360.6 pp | +135.8 pp | |
| LTM Mar 2026 | 6.6% | +108.0 pp | +165.0 pp | |
| LTM Mar 2026 | -40.5% | +24.7 pp | +32.2 pp | |
| LTM Sep 2026 | -60.8% | +103.5 pp | — | |
| LTM Sep 2026 | -150.2% | +165.7 pp | +146148.2 pp | |
| LTM Mar 2026 | -181.9% | -206.3 pp | +161.3 pp | |
| LTM Mar 2026 | -726.3% | +490.3 pp | -797.6 pp | |
| LTM Jun 2024 | -4534.8% | — | +623.6 pp | |
| LTM Mar 2026 | -618909.7% | -64222.0 pp | -565818.0 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding REPL) | -105.5% | +103.5 pp | +161.3 pp | |
Competitors are the stored peer set for REPL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.14M | 4.58M | 0 | 0 | 0 |
| Gross Profit | (4.14M) | (4.58M) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 57.49M | 80.65M | 126.53M | 174.96M | 189.45M |
| Selling, General & Admin | 21.13M | 36.26M | 0 | 0 | 0 |
| Operating Expenses | 78.62M | 116.91M | 177.08M | 234.77M | 261.63M |
| Depreciation & Amortization | 4.14M | 4.58M | 2.45M | 5.08M | 5.93M |
| EBITDA | (76.48M) | (114.41M) | (171.72M) | (227.77M) | (253.92M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (82.76M) | (121.48M) | (177.08M) | (234.77M) | (261.63M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 916K | 390K | 10.01M | 23.36M | 21.12M |
| Interest Expense | 3.06M | 2.22M | 4.16M | 6.66M | 7.89M |
| Other Income / Expenses | (915K) | 278K | 3.08M | 19.39M | 14.8M |
| Income Before Tax | (83.68M) | (121.21M) | (174M) | (215.39M) | (246.83M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (2.81M) | (3.17M) | 288K | 408K | 468K |
| Net Income | (80.87M) | (118.04M) | (174.28M) | (215.79M) | (247.3M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.75) | (2.26) | (2.99) | (3.24) | (3.07) |
| EPS (Diluted) | (1.75) | (2.26) | (2.99) | (3.24) | (3.07) |
| Weighted Avg Shares | 46.25M | 52.21M | 58.21M | 66.57M | 80.56M |
| Weighted Avg Shares (Diluted) | 46.25M | 52.21M | 58.21M | 66.57M | 80.56M |
Replimune Group, Inc.
NASDAQ:REPL
Intrinsic Alpha fair value
Locked
Current Price
$19.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.